# Early phase 1 lymphoma trials recruiting: 48 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 48 trials in early phase 1 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 lymphoma trials: 48 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 48
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07862010 | Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia | Hematology department of the 920th hospital | Early phase 1 | Recruiting | B-Cell Non-Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862010) |
| September 21, 2026 | NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Shanghai Simnova Biotechnology Co.,Ltd. | Early phase 1 | Not yet recruiting | B-cell Acute Lymphoblastic Leukemia | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830238) |
| June 26, 2026 | NCT07670260 | GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma | Chinese PLA General Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Large B-cell Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670260) |
| June 5, 2026 | NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | University of California, Irvine | Early phase 1 | Recruiting | Adenocarcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Ductal Carcinoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628634) |
| May 13, 2026 | NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Ruijin Hospital | Early phase 1 | Not yet recruiting | B-Cell Non-Hodgkin Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584850) |
| May 4, 2026 | NCT07563543 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563543) |
| May 1, 2026 | NCT07563023 | Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | West China Hospital | Early phase 1 | Not yet recruiting | HIV Associated Lymphoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563023) |
| April 30, 2026 | NCT07558538 | A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant... | Shanghai Zhongshan Hospital | Early phase 1 | Recruiting | ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558538) |
| April 23, 2026 | NCT07548697 | A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548697) |
| April 23, 2026 | NCT07546630 | Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma | Affiliated Hospital to Academy of Military Medical Sciences | Early phase 1 | Not yet recruiting | Relapsed/Refractory B-Cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546630) |
| February 24, 2026 | NCT07429461 | Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia | Zhejiang University | Early phase 1 | Recruiting | B-Cell Acute Lymphoblastic Leukemia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429461) |
| January 29, 2026 | NCT07376642 | A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary... | Suzhou Immunofoco Biotechnology Co., Ltd | Early phase 1 | Recruiting | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376642) |
| January 12, 2026 | NCT07335094 | A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic... | Zhujiang Hospital | Early phase 1 | Not yet recruiting | B Lymphoblastic Leukemia/Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335094) |
| December 31, 2025 | NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Recruiting | Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312630) |
| December 11, 2025 | NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | The General Hospital of Western Theater Command | Early phase 1 | Not yet recruiting | B-Cell Acute Lymphoblastic Leukemia, Adult | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277504) |
| December 1, 2025 | NCT07256353 | Allogeneic UCB-derived CAR-T for B-ALL | The General Hospital of Western Theater Command | Early phase 1 | Not yet recruiting | B-Cell Acute Lymphoblastic Leukemia, Adult | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256353) |
| October 9, 2025 | NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal... | Assistance Publique - Hôpitaux de Paris | Early phase 1 | Not yet recruiting | Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213882) |
| October 3, 2025 | NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell... | Grit Biotechnology | Early phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL)... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205315) |
| September 11, 2025 | NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | First Affiliated Hospital Xi'an Jiaotong University | Early phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168291) |
| September 9, 2025 | NCT07162012 | Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Early phase 1 | Recruiting | NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07162012) |
| August 3, 2025 | NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101705) |
| June 4, 2025 | NCT07003178 | A Study to Evaluate the Safety and Clinical Efficacy of STR-P004 | Starna Therapeutics | Early phase 1 | Not yet recruiting | Non Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07003178) |
| May 23, 2025 | NCT06986434 | CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation | Affiliated Hospital to Academy of Military Medical Sciences | Early phase 1 | Not yet recruiting | Relapsed or Refractory Plasma Cell Neoplasms, Lymphomas/Leukemias With Plasmacytic Differentiation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06986434) |
| May 16, 2025 | NCT06976437 | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | Sponsor not shown (see the record) | Early phase 1 | Recruiting | B Cell Lymphoma, Multiple Myeloma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976437) |
| January 27, 2025 | NCT06793241 | Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia | Zhejiang University | Early phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793241) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Zhejiang University | 4 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 |
| The First Affiliated Hospital of Soochow University | 2 |
| Affiliated Hospital to Academy of Military Medical Sciences | 2 |
| The General Hospital of Western Theater Command | 2 |
| University of California, Irvine | 1 |
| Salarius Pharmaceuticals, LLC | 1 |
| New York Medical College | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| Starna Therapeutics | 1 |
| Northwestern University | 1 |
| Fundacion Clinic per a la Recerca Biomédica | 1 |
| West China Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| University of Arizona | 1 |
| [PersonGen BioTherapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd) | 1 |
| AIDS Malignancy Consortium | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Zhujiang Hospital | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Suzhou Immunofoco Biotechnology Co., Ltd | 1 |
| 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 1 |
| Anhui Provincial Hospital | 1 |
| City of Hope Medical Center | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 30 |
| United States | 10 |
| Spain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
